Table 2.
Analysis of hearing parameters after treatment with TGF-β1 inhibitors.
| Strain | Group | ABR Parameter | n | Baseline | After treatment | ||
|---|---|---|---|---|---|---|---|
| Mean | SEM | Mean | SEM | ||||
| SSF | Threshold | 41 | 1.79 | 42 | 2.68 | ||
| IPL I-II | 1.03 | 0.04 | 1.03 | 0.01 | |||
| IPL I-IV | 5 | 2.63 | 0.03 | 2.57 | 0.03 | ||
| IPL II-IV | 1.60 | 0.05 | 1.54 | 0.04 | |||
| AMP I | 1260.22 | 178.17 | 1231.64 | 177.30 | |||
| MF1 | P17 | Threshold | 39 | 2.45 | 36 | 2.04 | |
| IPL I-II | 0.93 | 0.02 | 0.90 | 0.02 | |||
| IPL I-IV | 6 | 2.66 | 0.03 | 2.50 | 0.01 | ||
| IPL II-IV | 1.73 | 0.03 | 1.60 | 0.03 | |||
| AMP I | 1184.65 | 206.14 | 1488.37 | 220.30 | |||
| P144 | Threshold | 36 | 0.82 | 34 | 0.82 | ||
| IPL I-II | 0.92 | 0.01 | 0.90 | 0.01 | |||
| IPL I-IV | 6 | 2.65 | 0.04 | 2.47 | 0.03 | ||
| IPL II-IV | 1.73 | 0.03 | 1.57 | 0.02 | |||
| AMP I | 1191.12 | 106.64 | 1411.01 | 115.87 | |||
| SSF | Threshold | 43 | 1.22 | 39 | 1.63 | ||
| IPL I-II | 1.01 | 0.02 | 0.98 | 0.02 | |||
| IPL I-IV | 6 | 2.93 | 0.05 | 2.56 | 0.05 | ||
| IPL II-IV | 1.92 | 0.04 | 1.58 | 0.05 | |||
| AMP I | 1232.68 | 96.29 | 813.64 | 67.12 | |||
| C57 | P17 | Threshold | 43 | 1.22 | 42 | 1.63 | |
| IPL I-II | 0.91 | 0.04 | 0.91 | 0.01 | |||
| IPL I-IV | 6 | 2.66 | 0.10 | 2.53 | 0.05 | ||
| IPL II-IV | 1.75 | 0.07 | 1.62 | 0.05 | |||
| AMP I | 974.21 | 127.11 | 730.55 | 98.24 | |||
| P144 | Threshold | 41 | 1.63 | 40 | 1.22 | ||
| IPL I-II | 1.01 | 0.01 | 0.95 | 0.03 | |||
| IPL I-IV | 6 | 2.82 | 0.05 | 2.61 | 0.04 | ||
| IPL II-IV | 1.82 | 0.05 | 1.67 | 0.03 | |||
| AMP I | 1075.09 | 155.36 | 778.55 | 59.05 | |||
ABR thresholds (in dB SPL), interpeak latencies (in ms) and peak I amplitude (in nV) in response to click stimulus before and after systemic (intraperitoneal) treatment with TGF-β1 inhibitor peptides P17 and P144 (at 2.5 mg/kg/24 h) or saline (at 0.1 ml/10 g/24 h) for 15 days in MF1 and C57 mice. No statistically significant differences were found between baseline and post-treatment values (paired T-tests). MF1, HsdOla:MF1; C57, C57BL/6JOlaHsd IPL, interpeak latency; AMP, peak amplitude.